Современные аспекты лечения кислотозависимых заболеваний, ассоциированных с хеликобактериозом

Abstract

Целью исследования было изучение клинической эффективности использования L.reuteri для коррекции микробиоциноза и иммунного статуса у больных кислотозависимыми заболеваниями при проведении эрадикационной терапии. Обследовано 38 больных. Применение L.reuteri у данной категории больных приводит к улучшению и нормализации состояния кишечной микрофлоры, улучшению клеточного и гуморального иммунитета; Метою дослідження було вивчення клінічної ефективності використання L.reuteri для корекції мікробіоцинозу та імунного статусу у хворих на кислотозалежні захворювання при проведенні ерадикаційної терапії. Обстежено 38 хворих. Застосування L.reuteri у даної категорії хворих призводить до поліпшення та нормалізації стану кишкової мікрофлори, поліпшенню клітинного та гуморального імунітету; The aciddependent diseases of the digestive system are extremely common in family doctor′s practice. In addition, the relevance of this problem is due to a complex diagnostic search, the frequent development of serious complications.Since ancient times, the preparations containing normal flora have been used in medicine. The bifidumbakterii and lactobacilli are the main group of microorganisms used in the modern drugs. Lactobacillus reuteri are very interesting. They synthesize the short-chain fatty acids (lactic, acetic, formic,succinic), which reduces the pH of the intestinal contents, and as a result, the inhibition of reproduction putrefactive pathogenic microorganisms, ensures the stability of the intestinal microflora. L.Reuteri – a type of lactic acid bacteria in human strain was isolated from breast milk, mouth, stomach, small and large intestines, vagina. The using of L.reuteri has a positive effect in diseases of the gastrointestinal tract, protectes against infectious diseases, stimulates the immune system during the scientific research. Purpose of research was studying clinical efficiency of preparation L.Reuteri for correction microflora and the immune status at patients acid-dependent diseases at carrying out antihelicobacter therapies. It is surveyed 38 patients with aciddependent diseases, infected H.Pylori. Probiotic containing L.reuteri, named BioGaia drug was administered from the first day of eradication therapy (amoxicillin + clarithromycin + rabeprazole) 1 tablet once a day. The course of treatment was 2 weeks. Probiotic BioGaia was tolerated well by all observed patients. The side effects were not noted during treatment. When probiotic BioGaia was prescribed with other drugs it was not any undesirable interactions. State of the microflora improved in patients in the first group after two weeks of treatment with the probiotic BioGaia. Conducted monitoring bacteriological tests in those patients who had the original intestinal dysbiosis, allowed to improve the state of the microflora in 62% patients and to normalize in 20% patients. There is a normalization of IgA (it had increased significantly), reduction the number of IgG and IgM was not credible after treatment. After that the probiotic BioGaia was used the phagocytic activity of leukocytes has increased according to the phagocytic index. The use of probiotic containing L. reuteri, contributes to improving the functional state of the gastrointestinal tract, the normalization of a condition of intestinal microflora and improvement of a condition of cellular and humoral immunity according to indicators of T-lymphocytes, increasing the content of IgA, which is a substrate for the formation of secretory IgA, increasing of the phagocytic activity of leukocytes. Scientific research have proved the effectiveness and feasibility of a probiotic containing L.Reuteri in patients with aciddependent diseases during the eradication therapy for the prevention and correction of mikrobiotsinoz and immune status.